HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating for Sage Therapeutics with a maintained price target of $25.
October 09, 2024 | 10:55 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating for Sage Therapeutics, maintaining a price target of $25. This suggests that the firm does not expect significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $25 price target by HC Wainwright & Co. indicates that the analyst does not foresee significant changes in Sage Therapeutics' stock price in the short term. This suggests stability rather than volatility.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100